Russia’s vaccine is 91.6% effective against symptomatic coronavirus, interim trial results suggest.
No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at the injection site and weakness or low energy.
Interim data from the phase three trial of the Covid-19 vaccine from Russia, Gam-COVID-Vac (Sputnik V), suggests a two-dose regimen of the vaccine offers 91.6% efficacy.
The preliminary findings, published in The Lancet, are based on analysis of data from nearly 20,000 participants, three quarters of whom received the vaccine and one quarter received a placebo.
The jab is a two-part vaccine that includes two adenovirus vectors – recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S) – which have been modified to express the SARS-CoV-2 spike protein.